Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs STAA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STAA Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

STAA Overall Winner 6-Pillar Tally: DXR 2 – 4 STAA Matrix Metrics: DXR 6 – 4 STAA

As of Nov 16, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas STAA carries 34.0/100 (SELL) at $26.01 (23.4x Forward P/E, 6.8% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. STAA 34.0/100 SELL), STAA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -5894.3% operating margin) and revenue trajectory (-12.0% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STAA trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs STAA
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
STAA NASDAQ Head-to-Head Winner
Staar Surgical Co
Ophthalmic Goods
$26.01
-1.44% 1D
Market Cap $1.3B
TTM Revenue $328M
Forward P/E 23.4x
Beta / 30D Vol 0.50β · 63% Vol
Unified Composite Score
34.0 / 100 SELL
Tech 25.0 Fund 39.0 Flow 73.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $24.72 · SMA50: $23.02

6-Pillar Scorecard Institutional Category Breakdown (DXR 2 – 4 STAA)

Columns: Metric · DXR · STAA
1. Valuation Multiples STAA
Forward P/E 64.5x 23.4x
Trailing P/E 7.7x N/M
PEG Ratio N/M 0.76x
EV / Revenue N/M 3.7x
2. Growth & Scale DXR
Revenue Growth (YoY) +25.5% -12.0%
Earnings Growth (YoY) +329.3% -38.5%
TTM Revenue (USD) $31,360 $328M
Market Cap $49.5M $1.3B
3. Profitability & Quality DXR
Gross Margin 100.0% 73.6%
Operating Margin -5894.3% 6.8%
Net Profit Margin 19861.4% 0.2%
Return on Equity (ROE) 14.2% 0.1%
4. Balance Sheet & Cash Flow STAA
Cash Generation (TTM) N/A $18M
Cash Flow Margin N/A 5.4%
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $100M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STAA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 50.2% (6th %ile)
Put/Call OI Skew N/A 0.16x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat STAA
OpEx & R&D Intensity N/A 66.8% of Rev ($219M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (6) vs STAA (4)
Institutional Metric DXR STAA Criterion Row Edge
Market Capitalization
Scale
$49.5M $1.3B Larger Scale STAA
Trailing P/E Ratio
Valuation
7.7x N/M Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x 23.4x Lower Multiple STAA
Revenue Growth (YoY)
Growth
+25.5% -12.0% Higher Growth DXR
Operating Margin (TTM)
Profitability
-5894.3% 6.8% Higher Margin STAA
Net Profit Margin
Profitability
19861.4% 0.2% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% 0.1% Higher ROE DXR
52-Week Range Position
Momentum
2% ($8–$15) 51% ($16–$36) Stronger Trend STAA
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 0.50β · 63% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 34.0 / 100 (SELL) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $328M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 73.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.76x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) $18M ($100M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STAA +39.15 pp
DXR: -16.87% · STAA: +22.28%
3M Horizon STAA +22.34 pp
DXR: -19.66% · STAA: +2.68%
6M Horizon STAA +12.75 pp
DXR: -17.44% · STAA: -4.69%
1Y Horizon STAA +33.19 pp
DXR: -33.27% · STAA: -0.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs STAA. Trailing 12-month operating profitability (DXR -5894.3% vs STAA 6.8%) and valuation multiples (DXR 64.5x vs STAA 23.4x Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
STAA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$328M
Gross Margin73.6%
Op. Margin6.8%
ROE / Fwd P/E0.1% · 23.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STAA CONSOLIDATION
121d in phase · OBV DISTRIBUTION
Current IV 50.2%
IV Percentile 6th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact STAA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STAA Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.3B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 66.8% of Rev ($219M)
90D Engineering Disclosures 0 Published

Investor FAQ DXR vs STAA Key Questions & Quantitative Answers

As of Nov 16, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas STAA carries 34.0/100 (SELL) at $26.01 (23.4x Forward P/E, 6.8% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. STAA 34.0/100 SELL), STAA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -5894.3% operating margin) and revenue trajectory (-12.0% vs. +25.5% YoY). Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STAA trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with STAA at -12.0% YoY revenue growth and -38.5% YoY earnings growth on $328M TTM revenue (73.6% gross margin, 6.8% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $328M for STAA. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus 66.8% of Rev ($219M) (0 disclosures) for STAA.

STAA screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas STAA trades at 23.4x Forward P/E, N/M Trailing P/E, 0.76x PEG, and 3.7x EV/Revenue (5.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus STAA (0.1% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, STAA carries 50.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.50β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.